UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism

Arachchillage, DRJ; Mackie, IJ; Efthymiou, M; Chitolie, A; Hunt, BJ; Isenberg, DA; Khamashta, M; ... Cohen, H; + view all (2016) Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. Journal of Thrombosis and Haemostasis , 14 (11) pp. 2177-2186. 10.1111/jth.13475. Green open access

[img]
Preview
Text
Cohen_Rivaroxaban and complement activation in APS.pdf - ["content_typename_Accepted version" not defined]

Download (693kB) | Preview

Abstract

Background: Complement activation may play a major role in the pathogenesis of thrombotic antiphospholipid syndrome (APS). Coagulation proteases such as factor Xa can activate complement proteins. Aims: To establish whether rivaroxaban, a direct factor Xa inhibitor, limits complement activation compared to warfarin in APS patients with previous venous thromboembolism (VTE). Methods: 111 APS patients with previous VTE, on warfarin target INR 2.5, had blood samples taken at baseline and at day 42 after randomisation in the RAPS (Rivaroxaban in Antiphospholipid Syndrome) trial. Fifty-six patients remained on warfarin and 55 switched to rivaroxaban. Fifty-five normal controls (NC) were also studied. Markers of complement activation (C3a, C5a, terminal complement complex (SC5b-9) and Bb fragment), were assessed. Results APS patients had significantly higher complement activation markers compared to NC at both time points irrespective of the anticoagulant. There were no differences between the two patient groups at baseline, or patients remaining on warfarin at day 42. In 55 patients randomised to rivaroxaban, C3a, C5a and SC5b-9 were significantly lower at day 42; median (ng/mL) [confidence interval] 64 [29-125] vs 83 [35-147], 9 [2–15] vs 12 [4 -18] and 171 [56-245] vs 201 [66-350] respectively, but levels of Bb were unchanged. There were no correlations between rivaroxaban levels and complement activation markers. Conclusions: APS patients with previous VTE on warfarin exhibit significantly increased complement activation, which is likely to occur via the classical pathway, and is decreased by rivaroxaban administration. Rivaroxaban may therefore potentially provide benefit additional to its anticoagulant effect in this patient group by limiting complement activation.

Type: Article
Title: Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism
Open access status: An open access version is available from UCL Discovery
DOI: 10.1111/jth.13475
Publisher version: http://doi.org/10.1111/jth.13475
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: http://discovery.ucl.ac.uk/id/eprint/1508951
Downloads since deposit
68Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item